Product Information
RYBELSUS 14 MG TABLET is a brand product labeled by Novo Nordisk, priced at $33.1616 per EA under NDC 00169431430. Its NADAC has been published 231 times since Mar 23, 2022.
FDA first approved this application on Sep 20, 2019.
Strength
14 mg/1
Manufacturer
Novo NordiskNDC
00169431430
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
SEMAGLUTIDEApproval Type
New Drug (NDA)
FDA Application
NDA213051FDA Approved
9/20/2019
On Market Since
9/20/2019
Pharmacological Classes
Price Statistics
The NADAC for RYBELSUS 14 MG TABLET has been published 231 times since Mar 23, 2022, and over the history we have for it it has risen 15.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $33.1616 per EA |
|---|---|
| All-time high | $33.1671 (May 13, 2026) |
| All-time low | $28.5797 (Apr 20, 2022) |
| 52-week high | $33.1671 |
| 52-week low | $32.1894 |
| Median price | $31.1501 |
| Average price | $30.9356 |
| Largest weekly change | +4.9% (Jan 11, 2023) |
| Weeks tracked | 231 |
| Tracking since | Mar 23, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Oral Semaglutide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of RYBELSUS 14 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RYBELSUS 14 MG TABLET, manufactured by Novo Nordisk, is $33.1616 per EA (NDC 00169431430), effective Aug 19, 2026.
How has the price of RYBELSUS 14 MG TABLET changed over time?
Over the history we have for it, the NADAC for RYBELSUS 14 MG TABLET has risen 15.9%. It has been tracked across 231 weekly CMS publications since Mar 23, 2022.
What are the highest and lowest recorded NADAC prices for RYBELSUS 14 MG TABLET?
Since Mar 23, 2022, the NADAC for RYBELSUS 14 MG TABLET has ranged from a low of $28.5797 (Apr 20, 2022) to a high of $33.1671 (May 13, 2026), with a median of $31.1501 per EA.
Are there cheaper alternatives to RYBELSUS 14 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of RYBELSUS 14 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures RYBELSUS 14 MG TABLET?
RYBELSUS 14 MG TABLET (NDC 00169431430) is labeled by Novo Nordisk, and CMS classifies it as a brand product.